Skip to content

Transcranial Magnetic Stimulation in Bipolar Depression

A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00186758
Acronym
TMS
Enrollment
40
Registered
2005-09-16
Start date
2002-07-31
Completion date
2011-07-31
Last updated
2011-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Affective Disorder

Keywords

Transcranial Magnetic Stimulation, TMS

Brief summary

To compare antidepressant efficacy of left or right to sham Repetitive Transcranial Magnetic Stimulation (rTMS) to determine if non-responders can become responders if treated on the other side of the hemisphere (rTMS)

Detailed description

Patients will be assigned to one of 3 treatment arms for 10 days of treatment with either left high frequency or right high frequency, or sham rTMS. After 10 days of treatment, and no improvement, another 10 days of treatment follows, this time with the coil placed on the other hemisphere. Subjects will be followed for 2 months respectively with unrestricted treatment provided by their regular physician. Mood stabilizers will be continued throughout this trial.

Interventions

DEVICETranscranial Magnetic Stimulation (TMS)

Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days. Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -

Sponsors

Queen's University, Kingston, Ontario
CollaboratorOTHER
St. Joseph's Healthcare Hamilton
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Bipolar Depression * no physical health problems

Exclusion criteria

* Metal in head/neck or skull * History of Epilepsy * Pregnancy * Pacemaker

Design outcomes

Primary

MeasureTime frame
To compare antidepressant efficacy of right, left to shamwithin 9 weeks

Secondary

MeasureTime frame
To determine if QEEG activity correlates with antidepressant response to rTMSwithin 9 weeks
To determine if non-responders can become responders if treating the opposite hemispherewithin 9 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026